NCT00016692终止1 期
A Phase 1b Multicenter Double-Blind, Placebo-Controlled, Randomized Study on the Safety and Tolerability of Z-100 in Early HIV-1 Infected Patients
Zeria Pharmaceutical6 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 试验地点
- 6
研究概览
简要总结
The purpose of the study is to see if Z-100 (an investigational drug) treatment is safe in HIV patients who have never received treatment for their HIV, who have not been taking highly active antiretroviral therapy (HAART) for at least 8 weeks, or who have been stable on their current first or second HAART regimen for at least 12 weeks.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients may be eligible for this study if they:
- •Are HIV positive but do not show symptoms.
- •Are male or female, 18 years or older.
- •Have not received treatment for HIV.
- •Have received treatment but have discontinued HAART for at least 8 weeks prior to screening, have had stable viral loads on at least 2 separate time points at least 1 month apart including screening, and have had stable CD4 levels on at least 2 separate time points at least 1 month apart including screening.
- •Use birth control while on the study and during the follow-up period.
- •Have viral loads of 2,000 to 55,000 copies/ml within 2 weeks of randomization.
- •Have CD4 counts of greater than 350 cells/mm within 2 weeks of randomization.
- •Have a negative serum pregnancy test within 2 weeks of randomization (women able to have children).
排除标准
- •Patients will not be eligible for this study if they:
- •Have failed HAART treatment.
- •Have opportunistic infection or cancer.
- •Have a history of tuberculosis.
- •Have very abnormal laboratory test results.
- •Have heart, liver, kidney or nervous system conditions.
- •Have serious problems digesting and absorbing food or have serious long-term diarrhea within 4
- •weeks of randomization.
- •Have received radiation (localized is allowed) or chemotherapy within 30 days before randomization.
- •Have seizure disorders that cannot be controlled.
- •Have received any other drugs that affect the immune system or experimental drugs within 60 days before randomization.
- •Have had any vaccination within 15 days before randomization.
- •Have a mental condition which makes the patient unable to understand what the study is about and what it involves.
- •Have a history of alcohol or drug abuse, unless the investigator feels that it will not interfere with participation in the protocol.
- •Are pregnant or breast-feeding.
- •Have a history of being very sensitive to the study drug or similar drugs.
研究者
研究点 (6)
Loading locations...
相似试验
已完成
1 期
Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive SubjectsAsymptomatic HIV InfectionNCT02456558ApoPharma30
已完成
1 期
Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United StatesHIV InfectionsNCT03382418National Institute of Allergy and Infectious Diseases (NIAID)45
已完成
1 期
A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 Gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected AdultsHIV InfectionsNCT04224701International AIDS Vaccine Initiative48
终止
2 期
A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects.Human Immunodeficiency Virus InfectionNCT01737359RFS Pharma, LLC2
已完成
不适用
A Study on the Safety and Effectiveness of Adefovir Dipivoxil in Combination With Anti-HIV Therapy (HAART) in HIV-Positive PatientsHIV InfectionsNCT00002426Gilead Sciences390